Voyager Therapeutics Inc (VYGR)
8.43
-0.20
(-2.32%)
USD |
NASDAQ |
May 17, 16:00
8.43
0.00 (0.00%)
After-Hours: 20:00
Voyager Therapeutics Cash from Operations (Quarterly): 58.77M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 58.77M |
| December 31, 2023 | -23.76M |
| September 30, 2023 | -21.05M |
| June 30, 2023 | -0.835M |
| March 31, 2023 | 123.56M |
| December 31, 2022 | -12.24M |
| September 30, 2022 | -16.21M |
| June 30, 2022 | -18.48M |
| March 31, 2022 | 34.43M |
| December 31, 2021 | 11.20M |
| September 30, 2021 | -20.71M |
| June 30, 2021 | -22.72M |
| March 31, 2021 | -21.29M |
| December 31, 2020 | -21.98M |
| September 30, 2020 | -24.74M |
| June 30, 2020 | -21.20M |
| March 31, 2020 | -28.80M |
| December 31, 2019 | -23.36M |
| September 30, 2019 | -21.58M |
| Date | Value |
|---|---|
| June 30, 2019 | -31.56M |
| March 31, 2019 | 125.16M |
| December 31, 2018 | -24.35M |
| September 30, 2018 | -17.65M |
| June 30, 2018 | -22.50M |
| March 31, 2018 | 48.61M |
| December 31, 2017 | -14.83M |
| September 30, 2017 | -15.89M |
| June 30, 2017 | -16.34M |
| March 31, 2017 | -14.29M |
| December 31, 2016 | -13.09M |
| September 30, 2016 | -10.19M |
| June 30, 2016 | -9.714M |
| March 31, 2016 | -9.487M |
| December 31, 2015 | -9.557M |
| September 30, 2015 | -6.75M |
| June 30, 2015 | -6.982M |
| March 31, 2015 | 64.59M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-31.56M
Minimum
Jun 2019
123.56M
Maximum
Mar 2023
-5.128M
Average
-21.13M
Median
Cash from Operations (Quarterly) Benchmarks
| Ligand Pharmaceuticals Inc | 18.73M |
| Stereotaxis Inc | -2.346M |
| United Therapeutics Corp | 376.50M |
| MEI Pharma Inc | -2.928M |
| Agios Pharmaceuticals Inc | -99.87M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -96.06M |
| Cash from Financing (Quarterly) | 112.86M |
| Free Cash Flow | 8.233M |
| Free Cash Flow Per Share (Quarterly) | 0.9914 |
| Free Cash Flow to Equity (Quarterly) | 56.63M |
| Free Cash Flow to Firm (Quarterly) | 56.63M |
| Free Cash Flow Yield | 2.00% |